Legend Biotech Corp Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss
Legend Biotech Corp (LEGN) reported Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss of -$168.80 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-10.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss · last filed 2026-03-10
- Legend Biotech Corp gains losses on exchange differences on translation recognised in profit or loss for the quarter ending 2025-12-31 was -$3.40M, a 103.08% decline year-over-year.
- Legend Biotech Corp gains losses on exchange differences on translation recognised in profit or loss for the quarter ending 2025-09-30 was -$128.00K.
- Legend Biotech Corp gains losses on exchange differences on translation recognised in profit or loss for the quarter ending 2025-06-30 was -$109.99M, a 1002.54% decline year-over-year.
- Legend Biotech Corp gains losses on exchange differences on translation recognised in profit or loss for the quarter ending 2025-03-31 was -$55.19M, a 212.51% decline year-over-year.
| Period end | Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss 3 month | Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss 6 month | Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss 9 month | Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss 9 month as first filed | Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | -$3.40M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-10 | -$3.53M derived: sum of 2 quarters · filed 2026-03-10 | -$113.53M derived: sum of 3 quarters · filed 2026-03-10 | -$168.80M 20-F · filed 2026-03-10 | |
| 2025-09-30 | -$128.00K 6-K · filed 2025-11-12 | -$110.12M derived: sum of 2 quarters · filed 2025-11-12 | -$165.40M 6-K · filed 2025-11-12 | -$54.90M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2025-06-30 | -$109.99M 6-K · filed 2025-08-11 | -$165.19M 6-K · filed 2025-08-11 | -$54.77M derived: sum of 3 quarters · filed 2026-03-10 | -$116.59M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2025-03-31 | -$55.19M 6-K · filed 2025-05-13 | $55.22M derived: sum of 2 quarters · filed 2026-03-10 | -$6.60M derived: sum of 3 quarters · filed 2026-03-10 | $5.59M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2024-12-31 | $110.41M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-10 | $48.59M derived: sum of 2 quarters · filed 2026-03-10 | $60.78M derived: sum of 3 quarters · filed 2026-03-10 | $109.30M 20-F · filed 2026-03-10 | |
| 2024-09-30 | -$61.82M 6-K · filed 2025-11-12 | -$49.63M derived: sum of 2 quarters · filed 2025-11-12 | -$1.11M 6-K · filed 2025-11-12 | $0.00 6-K · filed 2024-11-12 | -$38.91M derived: sum of 4 quarters · filed 2026-03-10 |
| 2024-06-30 | $12.19M 6-K · filed 2025-08-11 | $60.70M 6-K · filed 2025-08-11 | $22.91M derived: sum of 3 quarters · filed 2026-03-10 | $33.04M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2024-03-31 | $49.06M 6-K · filed 2025-05-13 | $10.72M derived: sum of 2 quarters · filed 2026-03-10 | $20.86M derived: sum of 3 quarters · filed 2026-03-10 | $20.86M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2023-12-31 | -$38.34M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-10 | -$28.20M derived: sum of 2 quarters · filed 2026-03-10 | -$28.20M derived: sum of 3 quarters · filed 2026-03-10 | -$28.20M 20-F · filed 2026-03-10 | |
| 2023-09-30 | $10.14M derived: 6-K 9 month − 6-K 6 month · filed 2024-11-12 | $10.14M derived: sum of 2 quarters · filed 2024-11-12 | $10.14M 6-K · filed 2024-11-12 | ||
| 2023-06-30 | $0.00 derived: 6-K 6 month − 6-K 3 month · filed 2024-08-09 | $0.00 6-K · filed 2024-08-09 | |||
| 2023-03-31 | $0.00 6-K · filed 2024-05-13 |